Viracta Therapeutics, Inc.
viracta.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Nov 13, 2024. Its latest SEC filing is a 25-NSE from Jul 10, 2025.
10-Q for Q3 FY2024, filed Nov 13, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops an oral drug combination for patients with Epstein-Barr virus-associated lymphomas and solid tumors.
10-K for FY2023, filed Mar 7, 2024
Who Were Their Customers?
Viracta works with collaboration partners under agreements that can cover licenses, development or regulatory milestones, and royalties on sales of licensed products.
10-K for FY2023, filed Mar 7, 2024The Company evaluates collaboration arrangements to determine whether units of account within the collaboration arrangement exhibit the…View ↗
If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the…View ↗
Milestone PaymentsView ↗
RoyaltiesView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2024, filed Nov 13, 2024
−$10.6MView ↗
- ▼ −16% (Loss)
- vs −$12.6M in Q3 FY2023
-
Feb 5, 2025
Viracta terminated employees and began winding down operations
It is exploring strategic alternatives for its development programs; the CEO and CFO departed, and Craig R. Jalbert was appointed CEO and CFO.
Sources
8-K, filed Feb 5, 2025
On February 3, 2025, the Board of Directors (the “Board”) of Viracta Therapeutics, Inc. (the “Company”) approved the termination of its…View ↗
-
Jan 31, 2025
Nasdaq set Viracta shares for delisting and trading suspension
The company expected its shares to trade on the OTC Pink Open Market under VIRX.
Sources
8-K, filed Jan 31, 2025
On January 31, 2025, the Company received written notification (the “Delisting Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that…View ↗
From targeted inhibitors to virus-associated cancers
The older report described Sunesis developing targeted inhibitors for blood and solid cancers and maintaining partnered programs. The latest report focuses Viracta on an oral drug combination for Epstein-Barr virus-associated cancers.
10-K for FY2020, filed Feb 24, 2021 10-K for FY2023, filed Mar 7, 2024
Who Did They Compete With?
Competes with Atara Biotherapeutics, Coherus, and Junshi Biosciences
10-K for FY2023, filed Mar 7, 2024For Nana-val, Viracta’s proprietary HDAC inhibitor, nanatinostat, in combination with valganciclovir, Viracta is aware of several other…View ↗
Loading...
